Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan
PR Newswire
ROCKVILLE, Md. and TOKYO, July 30, 2026
Key Highlights:Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialize Kaigene's next-generation FcRn inhibitor, KG006, in Japan.Kaigene will receive a $5 million upfront payment and is eligible for up to a combined total of $22 million and ¥57.5 billion JPY (approximately $351 million) in development, regulatory, and sales milestone payments, plus tiered royalties on net sales.The agreement is expected to establish a robust framework for a three-way multi-regional clinical trial (MRCT) collaboration among Kaigene, Taisho and Celltrion, significantly accelerating the global clinical development of KG006.Taisho brings proven biologics expertise to the alliance, having extensive experience in the development and commercialization of Nanozora ®, an innovative anti-TNF VHH antibody therapeutic for the treatment of Rheumatoid Arthritis in Japan.ROCKVILLE, Md. and TOKYO, July 30, 2026 /PRNewswire/ -- Kaigene, Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho"), a leading Japanese pharmaceutical company, for the exclusive development and commercialization of Kaigene's next-generation human neonatal Fc receptor (hFcRn) inhibitor, KG006, in Japan.
